Literature DB >> 10670826

(N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.

H Zia1, J Leyton, M Casibang, V Hau, D Brenneman, M Fridkin, I Gozes, T W Moody.   

Abstract

The effects vasoactive intestinal peptide (VIP) antagonists were investigated on pancreatic cancer cell lines. (N-Stearyl, Norleucine17) VIP hybrid ((SN)VIPhyb) inhibited 125I-VIP binding to human Capan-2 cells with an IC50 value of 0.01 microM whereas VIP hybrid had an IC50 value of 0.2 microM. By RT-PCR and Northern blot, VPAC1 receptor mRNA was detected in CAPAN-2 cells. One microM (SN)VIPhyb and 10 microM VIPhyb inhibited the ability of 30 nM VIP to elevate cyclic AMP and increase c-fos mRNA. (SN)VIPhyb, 1 microM inhibited the clonal growth of CAPAN-2 cells in vitro. In vivo, (SN)VIPhyb (10 microg/day s.c.) inhibited CAPAN-2 xenograft growth in nude mice. These results indicate that (SN)VIPhyb is a pancreatic cancer VPAC receptor antagonist.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10670826     DOI： 10.1016/s0024-3205(99)00604-9

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  6 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

3.  Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.

Authors:  John P Vu; Mulugeta Million; Muriel Larauche; Leon Luong; Joshua Norris; James A Waschek; Charalabos Pothoulakis; Joseph R Pisegna; Patrizia M Germano
Journal:  J Mol Neurosci       Date:  2014-01-07       Impact factor: 3.444

Review 4.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

5.  The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Authors:  Saar Oz; Yanina Ivashko-Pachima; Illana Gozes
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

Review 6.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.